Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.57 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 4/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265773 | 0.84 | CYP1A2 (0.57) | PDK2PDK4AKR1B1CYP1A2POLB | |
| SCHEMBL31238639 | 0.84 | CYP1A2 (0.57) | PDK2PDK4AKR1B1CYP1A2POLB | |
| SCHEMBL28510693 | 0.83 | SMN1; SMN2 (0.41) | PDK2PDK4AKR1B1CYP1A2POLB | |
| SCHEMBL23972238 | 0.81 | AKR1B1 (0.45) | PDK2PDK4MAPK14AKR1B1CYP1A2 | |
| SCHEMBL11225066 | 0.78 | CYP1A2 (0.51) | MAPK14AKR1B1CYP1A2POLBCYP3A4 | |
| SCHEMBL12782420 | 0.78 | AKR1B1 (0.46) | AKR1B1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1972936 | 0.78 | PDK2 (0.55) | PDK2PDK4MAPK14AKR1B1CYP1A2 | |
| SCHEMBL1223198 | 0.78 | PDK2 (0.55) | PDK2PDK4MAPK14ATAD2PGR | |
| SCHEMBL2144278 | 0.78 | PDK2 (0.55) | PDK2PDK4MAPK14ATAD2PGR | |
| SCHEMBL13617327 | 0.78 | PDK2 (0.55) | PDK2PDK4MAPK14ATAD2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152210-B1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230159465-A1 | IMMUNOMODULATOR | HITGEN INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021130731-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-04-09 | — | — | US | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-1894932-A1 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer | Japan Tobacco, Inc. (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1761528-B1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | JAPAN TOBACCO INC (JP) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006119504-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-0780388-B1 | 5HT1Dalpha and 5HT2A ligands | LILLY CO ELI (GB) | 2001-08-16 | — | — | EP | disclosed |
| US-6166040-A | Indole compounds | ELI LILLY AND COMPANY LIMITED (GB) | 2000-12-26 | — | — | US | disclosed |
| EP-0963983-A1 | Indol-2-ones as serotonin modulators | ELI LILLY AND COMPANY LIMITED (GB) | 1999-12-15 | — | — | EP | disclosed |
| US-5773448-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1998-06-30 | — | — | US | disclosed |
| EP-0780388-A1 | 5HT1Dalpha and 5HT2A ligands | LILLY INDUSTRIES LIMITED (GB) | 1997-06-25 | — | — | EP | disclosed |
| US-4933336-A | Thiadiazinone, oxadiazinone and triazinone derivatives, and their use for treating acute or chronic heart disease | LABORATOIRES SOBIO S.A. (FR) | 1990-06-12 | — | — | US | disclosed |
| EP-0303418-A2 | Substituted indolones, useful in the treatment of heart or asthmatic diseases | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159465-A1 | IMMUNOMODULATOR | IL2, IL17A, IL2RA | PDK2 2977/4885PDK4 3984/4885MAPK14 1849/4885 |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | PDK2 918/4885PDK4 1166/4885MAPK14 1490/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | PDK2 831/4885PDK4 2358/4885MAPK14 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.